Stay updated on Seagen Press Releases

Sign up to get notified when there's something new on the Seagen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Seagen Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    Shifts page focus from a past trial-result announcement to future dividend news and a broader October 2025 timeline; removes a June 2025 item and a specific HYMPAVZI phase 3 result item.
    Difference
    10%
    Check dated 2025-10-13T09:28:29.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Added a major policy/impact headline about Pfizer and U.S. government drug-cost agreement; removed a financial dividend notice. Overall, the page content shifts toward substantive policy news rather than investor/financial updates.
    Difference
    8%
    Check dated 2025-10-06T05:57:16.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Updates add newer Pfizer news (trial results, regulatory opinions, licensing, corporate actions) and remove several older or duplicative notices; the page now emphasizes recent clinical and regulatory developments and strategic movements.
    Difference
    35%
    Check dated 2025-09-29T03:12:46.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    Adds a 2025-2026 COVID-19 vaccine topline data item, a September 2025 date, and an Accessibility Statement; removes the Pfizer BRAFTOVI oncology press release. Overall, the page moves toward vaccine news and policy content rather than oncology drug news.
    Difference
    15%
    Check dated 2025-09-14T19:58:43.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now includes the FDA approval of Pfizer and BioNTech’s COMIRNATY® vaccine for specific age groups, while the previous mention of Astellas and Pfizer’s XTANDI™ research has been removed.
    Difference
    15%
    Check dated 2025-08-31T12:09:25.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now includes information about the significant survival benefits of PADCEV™ Plus KEYTRUDA™ for bladder cancer patients, while a previous announcement regarding Pfizer's licensing agreement has been removed.
    Difference
    12%
    Check dated 2025-08-17T04:35:27.000Z thumbnail image

Stay in the know with updates to Seagen Press Releases

Enter your email address, and we'll notify you when there's something new on the Seagen Press Releases page.